Werewolf Therapeutics, Inc. HOWL
Set alert
0.99 USD -0.11 -10.35%
At close · Oct 30
0.99 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
0.97 Day range 1.09
0.308 52-week range 1.40
- YTD
- +55.54%
- 1 year
- -29.56%
- Open
- 1.09
- Prev close
- 1.10
- Mkt cap
- 47.93M
- Vol
- 415.56K
- Avg vol
- 6.73M
- EPS
- -0.73
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.97
- High
- 1.09
- Forward P/E
- -0.86
- Beta
- 0.41
- Short ratio
- 2.09
- Inst. own
- 72.62%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.11
- 200-d avg
- 3.31
- 1y target
- 12.00
2Y chart
Events in this range
- Nov 7, 2024Earnings: -0.38; estimate -0.41; surprise 7.32%
- Nov 19, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (61)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 2026 | 1 day ago |
| MACD: Buy Signal | Oct 29, 2026 | 2 days ago |
| MACD: Sell Signal | Oct 23, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 19, 2026 | 1 week ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| RSI: Overbought | Aug 21, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 18, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 4, 2026 | 2 months ago |
| SMA: Bearish | Jul 31, 2026 | 3 months ago |
| SMA: Bullish | Jul 24, 2026 | 3 months ago |
| RSI: Oversold | Jun 29, 2026 | 4 months ago |
| RSI: Oversold | Jun 17, 2026 | 4 months ago |
| RSI: Oversold | Jun 5, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 1, 2026 | 5 months ago |
| RSI: Oversold | May 15, 2026 | 5 months ago |
| SMA: Bearish | Apr 28, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 10, 2026 | 6 months ago |
| RSI: Overbought | Apr 6, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 1, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 30, 2026 | 7 months ago |
| RSI: Overbought | Mar 11, 2026 | 7 months ago |
| SMA: Bullish | Mar 9, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Feb 27, 2026 | 8 months ago |
| SMA: Bearish | Feb 20, 2026 | 8 months ago |
| SMA: Bullish | Feb 19, 2026 | 8 months ago |
| RSI: Oversold | Jan 15, 2026 | 9 months ago |
| RSI: Oversold | Jan 12, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 7, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 19, 2025 | 10 months ago |
| RSI: Oversold | Dec 18, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 26, 2025 | 11 months ago |
| RSI: Oversold | Nov 7, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bearish | Oct 29, 2025 | 1 year ago |
| SMA: Bullish | Oct 24, 2025 | 1 year ago |
| SMA: Bearish | Oct 23, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 8, 2025 | 1 year ago |
| RSI: Overbought | Sep 22, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 14, 2025 | 1 year ago |
| SMA: Bullish | Aug 13, 2025 | 1 year ago |
| SMA: Bearish | Jul 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 14, 2025 | 1 year ago |
| SMA: Bullish | Jul 11, 2025 | 1 year ago |
| SMA: Bearish | Jun 27, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 12, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| RSI: Oversold | Mar 26, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 18, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 11, 2025 | 1 year ago |
| RSI: Oversold | Feb 27, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 22, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 26, 2024 | 1 year ago |
| RSI: Oversold | Dec 13, 2024 | 1 year ago |
Key statistics
- Market cap
- 69.96M
- Enterprise value
- -15.19M
- Trailing P/E
- 0.00
- Forward P/E
- -0.86
- PEG ratio
- 0.00
- Price / sales
- 20.66
- Price / book
- 0.77
- EPS (TTM)
- -1.52
- Beta
- 0.41
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.39M
- Revenue growth
- 0.00%
- Free cash flow
- -27.67M
- Total cash
- 122.83M
- Total debt
- 36.78M
- Return on equity
- -61.56%
- Shares outstanding
- 44.56M
- Short % of float
- 4.67%
- 50-day average
- 2.11
- 200-day average
- 3.31
Analyst view
Consensus: none
Price target (mean) 12.00 +1116.9% upside
Now 0.9861
- Target (low)
- 8.00
- Target (mean)
- 12.00
- Target (high)
- 15.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.275.
Financials — quick view
HOWL Revenue — quarterly 21.00M
HOWL Net income — quarterly 3.67M
HOWL EPS — quarterly 0.08
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.41 | -0.38 | +0.03 | +7.32% |
| Aug 8, 2024 | Jun 1, 2024 | -0.38 | -0.43 | -0.05 | -13.16% |
| Aug 8, 2024 | Jun 1, 2024 | -0.38 | — | — | — |
| May 3, 2024 | Mar 1, 2024 | -0.35 | -0.39 | -0.04 | -11.43% |
| May 3, 2024 | Mar 1, 2024 | -0.35 | — | — | — |
| Mar 7, 2024 | Dec 1, 2023 | -0.43 | -0.33 | +0.10 | +23.26% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 26, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 26, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Jun 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- werewolftx.com
News
- Werewolf Therapeutics To Present Two Posters On WTX-124, WTX-330 Data At Upcoming SITC 2026 Annual Meeting
- Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
- New Strong Buy Stocks for October 9th
- Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Target Price of $4.00 According to Analysts
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
- Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ)
Your note
Sign in to keep a note on HOWL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jan 5, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 13.79% | 6,144,881 | 9.65M | Sep 29, 2024 |
| MPM Asset Management, LLC | 9.61% | 4,284,172 | 6.73M | Sep 29, 2024 |
| Pfm Health Sciences, Lp | 7.63% | 3,398,747 | 5.34M | Sep 29, 2024 |
| MPM BioImpact Capital LLC | 5.36% | 2,388,011 | 3.75M | Sep 29, 2024 |
| Bank of America Corporation | 4.83% | 2,153,717 | 3.38M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 4.49% | 2,000,594 | 3.14M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.80% | 800,282 | 1.26M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.52% | 676,891 | 1.06M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.88% | 392,161 | 615.69K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.70% | 310,654 | 487.73K | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.48% | 211,769 | 332.48K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 171,305 | 268.95K | Oct 30, 2024 |